Immix Biopharma Inc.

01/19/2022 | Press release | Distributed by Public on 01/19/2022 09:17

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles - Form 8-K